Anticoagulant and thrombolytic drugs. II. Clinical aspects.
D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001779:Blood Coagulation Factors; D003327:Coronary Disease / Q000188:drug therapy; D003374:Coumarins / Q000494:pharmacology; D004176:Dipyridamole / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D004336:Drug Antagonism; D004342:Drug Hypersensitivity; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010689:Phlebitis / Q000188:drug therapy; D010973:Platelet Adhesiveness / Q000187:drug effects; D049590:Postpartum Period / Q000187:drug effects; D011247:Pregnancy / Q000187:drug effects; D011655:Pulmonary Embolism / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D013997:Time Factors
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D003374:Coumarins; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D006493:Heparin